Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with pemetrexed and platinum-based chemotherapy within its marketing authorisation for previously treated EGFR-positive non-small-cell lung cancer.
Please note that following on from information provided to NICE by the company in February 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 3873

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 November 2024 Discontinued. Please note that following on from information provided to NICE by the company in February 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
19 April 2023 Suspended. For information, the company have announced that trial did not meet its primary endpoint and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
15 February 2021 - 15 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual